Video Experimental Relacionado
Updated: May 20, 2026
09:57
Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach
Published on: December 17, 2016
Las estructuras cristalinas del proteasoma inmunológico y constitutivo revelan diferencias en la especificidad del
Eva M Huber1, Michael Basler, Ricarda Schwab
1Center for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie, Technische Universität München, Garching D-85747, Germany.
Cell
|February 21, 2012
Resumen
Determinamos las estructuras de los proteasomas e inmunoproteasomas de ratón, revelando cómo el inhibidor PR-957 se dirige selectivamente a los inmunoproteasomas. Este hallazgo ayuda en el diseño de nuevos medicamentos para el cáncer y las enfermedades autoinmunes.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Biología Estructural Biología estructural.
- Inmunología Inmunología.
Sus antecedentes:
- Los proteasomas, cruciales para la presentación del antígeno, existen en formas constitutivas e inmunoproteasómicas con distintas subunidades catalíticas.
- Estas subunidades influyen en el repertorio péptidico presentado por las moléculas del complejo mayor de histocompatibilidad clase I (MHC-I).
Objetivo del estudio:
- Para aclarar la base estructural para la inhibición selectiva de los inmunoproteasomas por PR-957.7.
- Comprender las diferencias estructurales entre los proteasomas constitutivos y los inmunoproteasomas.
Principales métodos:
- Cristalografía de rayos X de proteasomas constitutivos y inmunoproteasomas de ratón (con y sin PR-957) a una resolución de 2,9 Å.
- Análisis estructural con resolución temporal del proteasoma de levadura: complejos PR-957.
Principales resultados:
- Se identificaron nuevas características catalíticas de la subunidad del inmunoproteasoma β5i/LMP7.
- PR-957 se une selectivamente a la subunidad β5i, no β5c, debido a las diferencias conformacionales en el bolsillo S1.
- El acoplamiento de ligandos se produce específicamente a través del grupo de cabeza reactiva y la cadena lateral P1.
Conclusiones:
- Los conocimientos estructurales apoyan el diseño racional de inhibidores selectivos del inmunoproteasoma.
- Estos inhibidores tienen potencial para el tratamiento de enfermedades asociadas con la producción aberrante de citoquinas, como el cáncer y los trastornos autoinmunes.
Más Videos Relacionados
Videos de Conceptos Relacionados
02:34Enzymes
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
01:17The Proteasome Structure
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...